Active cerebellum rTMS for Schizophrenia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
McLean Hospital, Belmont, MA
Schizophrenia+4 More
Repetitive Transcranial Magnetic Stimulation (rTMS) - Device
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study the investigators will be stimulating the brain to learn more about how TMS might improve these symptoms of schizophrenia.

Eligible Conditions

  • Schizophrenia
  • Schizoaffective Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: baseline

baseline
Auditory Hallucination Rating Scale (AHRS) Scale (AHRS)
Positive and Negative Syndrome Scale (PANSS)
Scale for the Assessment of Positive Symptoms (SAPS)
Week 1
functional connectivity

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Active cerebellum rTMS
1 of 2
Sham cerebellum rTMS
1 of 2
Active Control
Non-Treatment Group

68 Total Participants · 2 Treatment Groups

Primary Treatment: Active cerebellum rTMS · Has Placebo Group · N/A

Active cerebellum rTMS
Device
ActiveComparator Group · 1 Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) · Intervention Types: Device
Sham cerebellum rTMS
Device
ShamComparator Group · 1 Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS) · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline

Trial Background

Prof. Mark A. Halko, PhD
Principal Investigator
Mclean Hospital
Closest Location: McLean Hospital · Belmont, MA
2001First Recorded Clinical Trial
11 TrialsResearching Schizophrenia
125 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References